Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022

SELL
$4.09 - $6.5 $613 - $975
-150 Reduced 0.29%
51,400 $213,000
Q2 2022

Aug 15, 2022

SELL
$3.01 - $5.22 $26,969 - $46,771
-8,960 Reduced 14.81%
51,550 $207,000
Q1 2022

May 13, 2022

SELL
$4.83 - $7.35 $159 - $242
-33 Reduced 0.05%
60,510 $300,000
Q4 2021

Feb 11, 2022

BUY
$6.16 - $12.07 $24 - $48
4 Added 0.01%
60,543 $422,000
Q3 2021

Nov 12, 2021

SELL
$9.7 - $14.34 $6,304 - $9,321
-650 Reduced 1.06%
60,539 $605,000
Q2 2021

Aug 13, 2021

SELL
$13.43 - $19.16 $4,700 - $6,706
-350 Reduced 0.57%
61,189 $868,000
Q1 2021

May 13, 2021

SELL
$15.82 - $22.11 $32,446 - $45,347
-2,051 Reduced 3.23%
61,539 $1.01 Million
Q4 2020

Feb 10, 2021

BUY
$7.91 - $22.95 $791 - $2,295
100 Added 0.16%
63,590 $1.32 Million
Q3 2020

Nov 12, 2020

BUY
$7.36 - $9.87 $220 - $296
30 Added 0.05%
63,490 $483,000
Q2 2020

Aug 13, 2020

BUY
$4.67 - $8.95 $1,027 - $1,968
220 Added 0.35%
63,460 $529,000
Q4 2019

Feb 12, 2020

SELL
$2.57 - $4.73 $10,280 - $18,920
-4,000 Reduced 5.95%
63,240 $250,000
Q2 2019

Aug 13, 2019

BUY
$2.46 - $4.52 $65,436 - $120,231
26,600 Added 65.45%
67,240 $296,000
Q1 2019

May 13, 2019

SELL
$3.51 - $4.77 $3,159 - $4,293
-900 Reduced 2.17%
40,640 $161,000
Q3 2018

Nov 13, 2018

BUY
$5.42 - $6.99 $12,872 - $16,601
2,375 Added 6.06%
41,540 $286,000
Q1 2018

May 08, 2018

BUY
$4.66 - $7.08 $24,698 - $37,524
5,300 Added 15.65%
39,165 $255,000
Q4 2017

Feb 14, 2018

SELL
$3.73 - $6.37 $17,904 - $30,576
-4,800 Reduced 12.41%
33,865 $151,000
Q3 2017

Nov 15, 2017

BUY
$5.28 - $6.88 $204,151 - $266,015
38,665
38,665 $239,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $560M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.